<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359618</url>
  </required_header>
  <id_info>
    <org_study_id>D4130C00009</org_study_id>
    <nct_id>NCT01359618</nct_id>
  </id_info>
  <brief_title>Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart</brief_title>
  <official_title>A Single-centre, Randomised, Double-blind, Placebo Controlled Phase I Study in Two Parts: Part A to Assess a Safe and Tolerable Supratherapeutic Dose of TC-5214 After Single Ascending Oral Doses in Healthy Male Subjects, Followed by Part B: A Four-period Double-dummy Crossover Study to Investigate the Effect of 2 Single Doses (Therapeutic and Supratherapeutic) of TC-5214 on the QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two part study. Part A will determine the maximum tolerated dose of TC-5214
      administered to healthy male subjects in single ascending oral doses. This part of the study
      will define the highest dose of TC-5214 to be administered in Part B. Part B of this study
      will investigate the effect of TC-5214 on the electrical activity of the heart following
      single oral administration. The study will be carried out healthy male subjects in a four
      period crossover study with TC-5214 compared to placebo and oral moxifloxacin as a positive
      control. The safety, tolerability and pharmacokinetics of TC-5214 will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision to terminate
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: To examine the safety and tolerability of TC-5214. The following assessments will be measured and reported: The number of participants with adverse events</measure>
    <time_frame>Up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: To examine the safety and tolerability of TC-5214. The following assessments will be measured and reported: A change from baseline in laboratory assessments.</measure>
    <time_frame>Up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: To examine the safety and tolerability of TC-5214. The following assessments will be measured and reported: A change from baseline in vital signs.</measure>
    <time_frame>Up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: To examine the safety and tolerability of TC-5214. The following assessments will be measured and reported: A change from baseline in electrocardiogram (ECG).</measure>
    <time_frame>Up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: To examine the safety and tolerability of TC-5214. The following assessments will be measured and reported: A change from baseline in physical examination.</measure>
    <time_frame>Up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: The maximum mean change in time-matched ECG interval, measured from the onset of the QRS complex to the T point, using the best heart rate correction method (QTc).</measure>
    <time_frame>Up to 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: TC-5214 Plasma and urine pharmacokinetic variable to be measured: including, C max, time to C max, Area Under Curve (AUC) (0-t), terminal half life, cumulative amount of drug excreted unchanged into urine from zero to time and renal clearance</measure>
    <time_frame>Up to 72 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: A change in the maximum of the mean change in time-matched ECG interval, measured from the onset of the QRS complex</measure>
    <time_frame>Up to 24 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Assay sensitivity by measuring the effect of moxifloxacin 400 mg on QTc compared to placebo</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Male</condition>
  <arm_group>
    <arm_group_label>Part A 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TC-5214</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TC-5214 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TC-5214 8 mg + moxifloxacin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TC-5214 supratherapeutic dose + moxifloxacin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TC-5214 placebo + moxifloxacin 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TC-5214 placebo + moxifloxacin placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-5214</intervention_name>
    <description>Single dose, oral tablets</description>
    <arm_group_label>Part A 1</arm_group_label>
    <arm_group_label>Part B 1</arm_group_label>
    <arm_group_label>Part B 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Single dose, oral tablets</description>
    <arm_group_label>Part A 2</arm_group_label>
    <arm_group_label>Part B 3</arm_group_label>
    <arm_group_label>Part B 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Single dose, oral encapsulated tablet</description>
    <arm_group_label>Part B 3</arm_group_label>
    <other_name>Avelox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Moxifloxacin placebo comparator</intervention_name>
    <description>Single dose, oral encapsulated tablet</description>
    <arm_group_label>Part B 1</arm_group_label>
    <arm_group_label>Part B 2</arm_group_label>
    <arm_group_label>Part B 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male 18 to 50 years old inclusive with suitable veins for cannulation or
             repeated venipuncture

          -  Have a body mass index (BMI) between 19 and 30 kg/m2 inclusive and weigh at least 50
             kg

          -  Male subjects should be willing to use a double barrier method of contraception
             (condom with spermicide) from the first dose of investigational product until 3 months
             after the last dose of investigational product

          -  Be able to understand and comply with the requirements of the study as judged by the
             investigator

        Exclusion Criteria:

          -  History of any clinically significant medical, neurologic or psychiatric disease or
             disorder which, in the opinion of the Investigator and Sponsor may either put the
             subject at risk because of participation in the study, or influence the results of the
             subject's ability to participate in the study

          -  History or presence of gastrointestinal (including irritable bowel disease), hepatic,
             or renal disease or other condition known to interfere with the absorption,
             distribution, metabolism, or excretion of study drug. Subjects with a history of
             surgery on the gastrointestinal tract (not including appendectomy or cholecystectomy)
             should also be excluded

          -  History of seizure activity, including febrile seizures

          -  Prolonged QTcF &gt;450 ms or shortened QTcF &lt;340 ms, or family history of Long QT
             Syndrome

          -  Use of concomitant medications that prolong QT/QTc interval
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans A Eriksson, MD, PhD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darren Wilbraham, MBBS DCPSA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drug Research Unit at Guy's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brendan Smyth, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2011</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>December 11, 2012</last_update_submitted>
  <last_update_submitted_qc>December 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>healthy</keyword>
  <keyword>major depressive disorder</keyword>
  <keyword>thorough QT</keyword>
  <keyword>maximum tolerated dose</keyword>
  <keyword>elimination</keyword>
  <keyword>heart electrical signal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

